Raimondo De Cristofaro

List of Publications by Year
in descending order

173	4,692	109321	128289
papers	citations	35 h-index	60 g-index

177	177	177	5801
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. Journal of Hepatology, 2009, 51, 682-689.	3.7	409
2	Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment. World Journal of Gastroenterology, 2010, 16, 143.	3.3	248
3	Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Journal of the American College of Cardiology, 2009, 53, 667-677.	2.8	234
4	Binding of Thrombin to Glycoprotein Ib Accelerates the Hydrolysis of Par-1 on Intact Platelets. Journal of Biological Chemistry, 2001, 276, 4692-4698.	3.4	193
5	The Bovine Basic Pancreatic Trypsin Inhibitor (Kunitz Inhibitor): A Milestone Protein. Current Protein and Peptide Science, 2003, 4, 231-251.	1.4	163
6	High-Mobility Group Box-1 Protein Promotes Angiogenesis After Peripheral Ischemia in Diabetic Mice Through a VEGF-Dependent Mechanism. Diabetes, 2010, 59, 1496-1505.	0.6	110
7	Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. Journal of Clinical Investigation, 2007, 117, 1951-1960.	8.2	105
8	Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica, 2010, 95, 2022-2030.	3.5	95
9	The effect of shear stress on protein conformation. Biophysical Chemistry, 2010, 153, 1-8.	2.8	82
10	Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB Journal, 2010, 24, 3970-3980.	0.5	75
11	Congenital Prothrombin Deficiency: An Update. Seminars in Thrombosis and Hemostasis, 2013, 39, 596-606.	2.7	68
12	Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. Journal of Thrombosis and Haemostasis, 2003, 1, 250-256.	3.8	67
13	The Asp272â€“Glu282 Region of Platelet Glycoprotein IbÎ± Interacts with the Heparin-binding Site of Î±-Thrombin and Protects the Enzyme from the Heparin-catalyzed Inhibition by Antithrombin III. Journal of Biological Chemistry, 2000, 275, 3887-3895.	3.4	61
14	Thrombin Domains: Structure, Function and Interaction with Platelet Receptors. Journal of Thrombosis and Thrombolysis, 2003, 15, 151-163.	2.1	56
15	Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radical Biology and Medicine, 2010, 48, 446-456.	2.9	56
16	Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. Journal of Translational Medicine, 2012, 10, 247.	4.4	56
17	Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusionâ€body myopathy muscle. Journal of Neurochemistry, 2008, 105, 971-981.	3.9	53
18	Congenital Prothrombin Deficiency. Seminars in Thrombosis and Hemostasis, 2009, 35, 367-381.	2.7	53

#	Article	IF	Citations
19	High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia, 2012, 55, 236-244.	6.3	51
20	Haemostatic system in inflammatory bowel diseases: New players in gut inflammation. World Journal of Gastroenterology, 2011, 17, 594.	3.3	50
21	Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. Journal of Thrombosis and Haemostasis, 2015, 13, 1226-1237.	3.8	48
22	Structural and Functional Mapping of the Thrombin Domain Involved in the Binding to the Platelet Glycoprotein Ibâ€. Biochemistry, 2001, 40, 13268-13273.	2.5	47
23	Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia. American Journal of Cardiology, 2001, 87, 16-20.	1.6	46
24	Prostaglandin E2Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 391-402.	2.5	45
25	Italian intersociety consensus on DOAC use in internal medicine. Internal and Emergency Medicine, 2017, 12, 387-406.	2.0	44
26	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	3.7	44
27	Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13. Journal of Biological Chemistry, 2005, 280, 23295-23302.	3.4	43
28	Linkage between proton binding and amidase activity in human .alpha.-thrombin: effect of ions and temperature. Biochemistry, 1991, 30, 7913-7924.	2.5	40
29	A Novel Venombin B from Agkistrodon contortrix contortrix:â€‰ Evidence for Recognition Properties in the Surface around the Primary Specificity Pocket Different from Thrombin. Biochemistry, 2000, 39, 10294-10308.	2.5	40
30	Impaired primary hemostasis with normal platelet function in Duchenne muscular dystrophy during highly-invasive spinal surgery. Neuromuscular Disorders, 2005, 15, 532-540.	0.6	40
31	Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Internal and Emergency Medicine, 2016, 11, 959-967.	2.0	40
32	Thrombin-Induced Platelet Activation Is Inhibited by High- and Low-Molecular-Weight Heparin. Circulation, 1999, 99, 3308-3314.	1.6	39
33	Mechanisms of the interaction between twoADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Human Mutation, 2006, 27, 330-336.	2.5	39
34	Fluorinated Benzyloxyphenyl Piperidine-4-carboxamides with Dual Function against Thrombosis: Inhibitors of Factor Xa and Platelet Aggregation. Journal of Medicinal Chemistry, 2009, 52, 1018-1028.	6.4	38
35	Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells. Molecules, 2013, 18, 10132-10145.	3.8	38
36	Carbon monoxide and oxygen binding to human hemoglobin F0. Biochemistry, 1989, 28, 2631-2638.	2.5	36

#	Article	IF	Citations
37	Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. Expert Opinion on Therapeutic Patents, 2010, 20, 229-250.	5.0	35
38	Phenomenological analysis of the clotting curve. The Protein Journal, 1991, 10, 455-468.	1.1	34
39	Fibrinogen-elongated Î³ Chain Inhibits Thrombin-induced Platelet Response, Hindering the Interaction with Different Receptors. Journal of Biological Chemistry, 2008, 283, 30193-30204.	3.4	34
40	The linkage between binding of the C-terminal domain of hirudin and amidase activity in human Î±-thrombin. Biochemical Journal, 1993, 289, 475-480.	3.7	33
41	Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. Clinical Science, 2011, 121, 555-564.	4.3	32
42	Mechanochemistry of von Willebrand factor. Biomolecular Concepts, 2019, 10, 194-208.	2.2	32
43	Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII. Biochemical Journal, 2003, 373, 593-601.	3.7	30
44	The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding. FEBS Journal, 2006, 273, 159-169.	4.7	30
45	Ristocetin-induced self-aggregation of von Willebrand factor. European Biophysics Journal, 2010, 39, 1597-1603.	2.2	30
46	Thrombin Interaction with Platelet GPIB: Role of the Heparin Binding Domain. Thrombosis and Haemostasis, 1997, 77, 735-740.	3.4	30
47	The Oxidative Modification of Von Willebrand Factor Is Associated with Thrombotic Angiopathies in Diabetes Mellitus. PLoS ONE, 2013, 8, e55396.	2.5	30
48	Effect of High- and Low-Molecular-Weight Heparins on Thrombin-Thrombomodulin Interaction and Protein C Activation. Circulation, 1998, 98, 1297-1301.	1.6	29
49	Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood, 2008, 112, 1085-1090.	1.4	29
50	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. Internal and Emergency Medicine, 2018, 13, 651-660.	2.0	29
51	Binding of the bovine basic pancreatic trypsin inhibitor (Kunitz) to human Î±-, Î²- and Î³-thrombin; a kinetic and thermodynamic study. BBA - Proteins and Proteomics, 1988, 956, 156-161.	2.1	28
52	Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood, 2002, 100, 1347-1353.	1.4	28
53	Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and theÎ±-granule content in the patient and four relatives. Journal of Thrombosis and Haemostasis, 2007, 5, 551-559.	3.8	28
54	Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thrombosis and Haemostasis, 2011, 105, 381-385.	3.4	27

#	Article	IF	Citations
55	Î²2-GlycoproteinÂI binds to thrombin and selectively inhibits the enzyme procoagulant functions. Journal of Thrombosis and Haemostasis, 2013, 11, 1093-1102.	3.8	27
56	Oxidation of Human Î±-Thrombin by the Myeloperoxidase-H2O2-chloride System: Structural and Functional Effects. Thrombosis and Haemostasis, 2000, 83, 253-261.	3.4	26
57	Pain assessment and management in haemophilia: A survey among Italian patients and specialist physicians. Haemophilia, 2018, 24, 766-773.	2.1	26
58	Onâ€pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens. Clinical Pharmacology and Therapeutics, 2017, 102, 849-858.	4.7	24
59	Meningeal hematopoiesis causing exophthalmus and hemiparesis in myelofibrosis: Effect of radiotherapy: A case report. Cancer, 1988, 62, 2346-2349.	4.1	23
60	Nucleotide-Derived Thrombin Inhibitors: A New Tool for an Old Issue. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2009, 7, 19-28.	1.0	23
61	Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA. Blood, 2010, 115, 2065-2072.	1.4	23
62	The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. Blood, 2010, 116, 5371-5376.	1.4	23
63	Modulation of thrombin-fibrinogen interaction by specific ion effects. Biochemistry, 1992, 31, 257-265.	2.5	22
64	Binding of human Î±-thrombin to platelet GpIb: energetics and functional effects. Biochemical Journal, 1998, 332, 643-650.	3.7	22
65	In vivo and in vitro effects of different anaesthetics on platelet function. British Journal of Haematology, 2004, 125, 79-82.	2.5	22
66	Mechanistic Studies on ADAMTS13 Catalysis. Biophysical Journal, 2008, 95, 2450-2461.	0.5	22
67	The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 289-293.	3.5	22
68	Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. Journal of Thrombosis and Haemostasis, 2011, 9, 1744-1751.	3.8	22
69	The expanding spectrum of PRPS1-associated phenotypes: three novel mutations segregating with X-linked hearing loss and mild peripheral neuropathy. European Journal of Human Genetics, 2015, 23, 766-773.	2.8	22
70	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.4	22
71	Effect of protons on the amidase activity of human Î±-thrombin. Journal of Molecular Biology, 1990, 216, 1077-1085.	4.2	21
72	Thermodynamics of Substrates and Reversible Inhibitors Binding to the Active Site Cleft of Human Î±-thrombin. Journal of Molecular Biology, 1994, 239, 569-577.	4.2	21

#	Article	IF	Citations
73	A Natural Prothrombin Mutant Reveals an Unexpected Influence of A-chain Structure on the Activity of Human Î±-Thrombin. Journal of Biological Chemistry, 2004, 279, 13035-13043.	3.4	21
74	Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy. Journal of Thrombosis and Thrombolysis, 2019, 48, 528-531.	2.1	21
75	Conformational Transitions Linked to Active Site Ligation in Human Thrombin: Effect on the Interaction with Fibrinogen and the Cleavable Platelet Receptor. Journal of Molecular Biology, 1995, 245, 447-458.	4.2	19
76	Plasma Protein Oxidation Is Associated with an Increase of Procoagulant Markers Causing an Imbalance between Pro- and Anticoagulant Pathways in Healthy Subjects. Thrombosis and Haemostasis, 2002, 87, 58-67.	3.4	19
77	Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Haemophilia, 2014, 20, e243-50.	2.1	19
78	Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. Biochemical Journal, 2012, 442, 423-432.	3.7	18
79	A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfusion, 2019, 17, 391-398.	0.4	18
80	Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF). Journal of Biological Chemistry, 2006, 281, 30400-30411.	3.4	17
81	Kinetic study of von Willebrand factor self-aggregation induced by ristocetin. Biophysical Chemistry, 2009, 144, 101-107.	2.8	17
82	Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTSâ€13. Journal of Thrombosis and Haemostasis, 2011, 9, 1620-1627.	3.8	17
83	Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors. Current Medicinal Chemistry, 2011, 18, 2205-2214.	2.4	17
84	Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia, 2020, 26, 937-945.	2.1	17
85	Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Human Immunology, 2009, 70, 360-373.	2.4	16
86	Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: Effects on platelet function in the systemic circulation and across the filter. Thrombosis Research, 2010, 126, 24-31.	1.7	16
87	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16
88	Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a caseâ€"control study. Blood Coagulation and Fibrinolysis, 2021, 32, 285-289.	1.0	16
89	Modulation of thrombin-hirudin interaction by specific ion effects. Journal of Molecular Biology, 1992, 226, 263-269.	4.2	15
90	Effect of Sodium on the Energetics of Thrombin â€" Thrombomodulin Interaction and its Relevance for Protein C Hydrolysis. Journal of Molecular Biology, 1996, 258, 190-200.	4.2	15

#	Article	IF	Citations
91	Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature. Journal of Cellular and Molecular Medicine, 2011, 15, 625-634.	3.6	15
92	The typeÂ2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress. Journal of Thrombosis and Haemostasis, 2013, 11, 1688-1698.	3.8	15
93	PROTEOLYTIC PROCESSING OF VON WILLEBRAND FACTOR BY ADAMTS13 AND LEUKOCYTE PROTEASES. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013058.	1.3	15
94	Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 <scp>AICE</scp> survey. Haemophilia, 2014, 20, e128-35.	2.1	15
95	Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity. Biochemistry, 2014, 53, 6992-7001.	2.5	15
96	Temperature- and pH-dependence of the oxygen-binding reaction of human fetal haemoglobin. Biochemical Journal, 1989, 260, 617-619.	3.7	14
97	Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. Thrombosis and Haemostasis, 2003, 89, 348-354.	3.4	14
98	Homocysteinemia is inversely correlated with platelet count and directly correlated with sE- and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase. Platelets, 2005, 16, 185-190.	2.3	14
99	Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. Journal of Translational Medicine, 2010, 8, 114.	4.4	14
100	The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2016, 115, 51-62.	3.4	14
101	Human platelet glycocalicin purification by phenyl boronate affinity chromatography coupled to anion-exchange high-performance liquid chromatography. Biomedical Applications, 1988, 426, 376-380.	1.7	13
102	Allosteric equilibria in the binding of fibrinogen to platelets.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 8473-8476.	7.1	13
103	Allosteric modulation of BPTI interaction with human alpha- and zeta-thrombin. FEBS Journal, 1999, 260, 97-102.	0.2	13
104	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	2.5	13
105	Effect of temperature on the association step in thrombin-fibrinogen interaction. Biochemical Journal, 1993, 294, 563-567.	3.7	12
106	Structure and Proteolytic Properties of ADAMTS13, A Metalloprotease Involved in the Pathogenesis of Thrombotic Microangiopathies. Progress in Molecular Biology and Translational Science, 2011, 99, 105-144.	1.7	12
107	Effects of protons on the thrombin-fibrinogen interaction. FEBS Journal, 1994, 219, 1013-1021.	0.2	11
108	Inherited Macrothrombocytopenia with Distinctive Platelet Ultrastructural and Functional Features. Thrombosis and Haemostasis, 2000, 83, 35-41.	3.4	11

#	Article	IF	Citations
109	ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study. Digestive and Liver Disease, 2022, 54, 1672-1680.	0.9	11
110	High-performance liquid chromatography in protein sequence determinations. Journal of Chromatography A, 1988, 440, 231-251.	3.7	10
111	Linkage between proton binding and amidase activity in human .gamma.-thrombin. Biochemistry, 1992, 31, 1147-1153.	2.5	10
112	Duodenal and gastric Dieulafoy's lesions in a patient with type 2A von Willebrand's disease. Gastrointestinal Endoscopy, 2005, 61, 322-325.	1.0	10
113	Inhibition of fibrinogen binding to human platelets by blockage of Na+H+ exchange. Biochemical and Biophysical Research Communications, 1989, 161, 1228-1232.	2.1	9
114	Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 413-421.	2.3	9
115	The linkage between adenosine nucleotide binding and amidase activity in human Î±-thrombin. Biophysical Chemistry, 1990, 36, 77-84.	2.8	8
116	Prothrombotic response to coronary angioplasty in patients with unstable angina and raised C-reactive protein. Journal of Thrombosis and Thrombolysis, 2002, 14, 131-138.	2.1	8
117	A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking. Thrombosis Research, 2014, 133, 481-487.	1.7	8
118	Polypharmacy in the elderly: A population based cross-sectional study in Lazio, Italy. European Geriatric Medicine, 2016, 7, 484-487.	2.8	8
119	Diagnostic testing for differential diagnosis in Thrombotic Microangiopathies. Turkish Journal of Haematology, 2019, 36, 222-229.	0.5	8
120	Modeling ADAMTS13-von Willebrand Factor interaction: Implications for oxidative stress-related cardiovascular diseases and type 2A von Willebrand Disease. Biophysical Chemistry, 2012, 160, 1-11.	2.8	7
121	Diagnosis and management of cerebral venous sinus thrombosis in children: a single-center retrospective analysis. Child's Nervous System, 2021, 37, 153-160.	1.1	7
122	Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients?. Aging Clinical and Experimental Research, 2021, 33, 2335-2343.	2.9	7
123	Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector. Biochemical Journal, 1995, 310, 49-53.	3.7	6
124	Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban. Liver International, 2017, 37, 1251-1251.	3.9	6
125	Noncanonical type 2B von Willebrand disease associated with mutations in the VWF Dâ€²D3 and D4 domains. Blood Advances, 2020, 4, 3405-3415.	5.2	6
126	Thrombin interaction with platelet GpIb: structural mapping and effects on platelet activation (review).. International Journal of Molecular Medicine, 1999, 3, 363-71.	4.0	5

#	Article	IF	Citations
127	The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency. British Journal of Haematology, 2004, 127, 576-584.	2.5	5
128	Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. ESC Heart Failure, 2019, 6, 884-888.	3.1	5
129	Indoleamine 2,3-Dioxygenase (IDO) Is Expressed by Multiple Myeloma Plasma Cells and Promotes the Differentiation of Regulatory T Cells: Investigations into the Role of Hepatocyte Growth Factor.. Blood, 2008, 112, 1680-1680.	1.4	5
130	COX-2 Inhibition Suppresses the Interferon-Î³-Induced Expression of Indoleamine 2,3-Dioxygenase (IDO) in Human Leukemia Cell Lines.. Blood, 2008, 112, 1623-1623.	1.4	5
131	Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. Thrombosis and Haemostasis, 2003, 89, 348-54.	3.4	5
132	Two Naturally Occurring Mutations on FVII Gene (S363I-W364C) Altering Intrinsic Catalytic Activity. Thrombosis and Haemostasis, 2002, 88, 750-755.	3.4	4
133	Thrombinâ€mediated impairment of fibroblast growth factorâ€2 activity. FEBS Journal, 2009, 276, 3277-3289.	4.7	4
134	Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels. Thrombosis and Haemostasis, 2018, 118, 1701-1712.	3.4	4
135	Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. TH Open, 2019, 03, e123-e131.	1.4	4
136	A novel factorâ€ƒXI missense mutation (Val371Ile) in the activation loop is responsible for a case of mild typeâ€ƒII factorâ€ƒXI deficiency. FEBS Journal, 2007, 274, 6128-6138.	4.7	3
137	Response: Further thoughts on the â€œphantomâ€•Î”6/7 FXI isoform. Blood, 2010, 116, 1186-1187.	1.4	3
138	ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study. Journal of Cardiovascular Medicine, 2021, 22, 175-179.	1.5	3
139	Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus. Journal of Clinical Medicine, 2022, 11, 801.	2.4	3
140	Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience. Viruses, 2022, 14, 1133.	3.3	3
141	Purification of the isolated Î²-chain of adult human haemoglobin from its post-translational modification. Biomedical Applications, 1989, 494, 310-317.	1.7	2
142	Kinetics of Free Platelet Decrease After ADP: Effect of Fibrinogen Binding Inhibitors. Platelets, 1995, 6, 152-159.	2.3	2
143	Sudden nasal bleeding and brodifacoum: A case of accidental exposure or attempted homicide?. Legal Medicine, 2020, 47, 101772.	1.3	2
144	Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?. Journal of the American College of Cardiology, 2021, 77, 3231-3232.	2.8	2

#	Article	IF	Citations
145	Effect of Thrombomodulin on the Molecular Recognition and Early Catalytic Events in Thrombin-Protein C Interaction. Thrombosis and Haemostasis, 1996, 76, 556-560.	3.4	2
146	In Vitro Expression Studies of Two Mutations on the Metalloprotease and First Cub Domains of the ADAMTS-13 Gene Leading to Severe ADAMTS-13 Deficiency and Chronic Recurrent TTP.. Blood, 2004, 104, 514-514.	1.4	2
147	The use of viscoelastic haemostatic assays in non-cardiac surgical settings: a systematic review and meta-analysis. Blood Transfusion, 2018, 16, 224-226.	0.4	2
148	The p. <scp>P1127S</scp> pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor <scp>LRP1</scp> : clinical phenotype and pathogenic mechanisms. Journal of Thrombosis and Haemostasis, 0, , .	3.8	2
149	Fibrinogen Milano IV (A Î± 16 Argâ†'His): characterization of its abnormal interaction with human Î±-thrombin. Biochemical Journal, 1994, 302, 623-624.	3.7	1
150	Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet, The, 2002, 360, 257.	13.7	1
151	Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against COVID-19 pandemic: What pathogenesis?. European Journal of Internal Medicine, 2021, 91, 88-89.	2.2	1
152	Hemophilia A and von Willebrand deficiency: therapeutic implications. Blood Coagulation and Fibrinolysis, 2020, 31, 397-401.	1.0	1
153	Graphical representation of michaelis-menten kinetics: Analysis of initial rate data through a difference equation. Biochemical Education, 1990, 18, 13-14.	0.1	0
154	Kinetic Aspects of Release of Fibrinopeptides AP and AY by Human Alpha-Thrombin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1991, 21, 85-90.	0.3	0
155	Conformational Transitions in Factor VIIa: Can We Stabilize the Inactive Form of the Enzyme?. Thrombosis and Haemostasis, 2002, 87, 4-6.	3.4	0
156	Anticoagulation in ischaemic heart disease. Heart, 2006, 92, 1011-1012.	2.9	0
157	Reduced portal flow-rate as predictive factor of portal vein thrombosis development in patients with liver cirrhosis. Digestive and Liver Disease, 2007, 39, A26.	0.9	0
158	Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2010, 8, 416-418.	3.8	0
159	Sirtuin 5, vascular endothelium and fibrinolysis: a deadly embrace?. Cardiovascular Research, 2021, 117, 2145-2147.	3.8	0
160	Localization and Function of Platelet ADAMTS-13.. Blood, 2005, 106, 3967-3967.	1.4	0
161	Molecular Mapping of the Chloride Binding Site in von Willebrand Factor (VWF): Energetics and Conformational Effects on the ADAMTS-13 Interaction with Wild Type and Type 2B R1306W VWF Forms.. Blood, 2006, 108, 333-333.	1.4	0
162	Thrombospondin-1 as a Modulator of ADAMTS13 Activity.. Blood, 2007, 110, 3711-3711.	1.4	0

#	Article	IF	Citations
163	Functional IDO Is Expressed on CD34+- and Monocyte-Derived Dendritic Cells According to Differentiation Status.. Blood, 2008, 112, 1552-1552.	1.4	0
164	Relevance of Chloride Binding to Von Willebrand Factor in Type 2B Von Willebrand Disease Patients.. Blood, 2008, 112, 3384-3384.	1.4	0
165	The Fibrinogen Elongated Î³-Chain Inhibits Thrombin-Induced Platelet Response, Hindering the Interaction with Different Receptors.. Blood, 2008, 112, 2023-2023.	1.4	0
166	Indoleamine 2,3-Dioxygenase Is Expressed and Functionally Active in Human Dermal Dendritic Cells, but Not in Epidermal Langherans Cells.. Blood, 2009, 114, 278-278.	1.4	0
167	The R1306W Type 2B Natural Mutation of Von Willebrand Factor Dramatically Enhances the Multimer Sensitivity to Shear Stress. Blood, 2012, 120, 3306-3306.	1.4	0
168	Indoleamine 2,3-Dioxygenase-1 (IDO1) Is Expressed by a Subset of Childhood Acute Myeloid Leukemias and Restrains IFN-Î³ Production by T Cells. Blood, 2012, 120, 1430-1430.	1.4	0
169	Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests. Blood, 2019, 134, 1178-1178.	1.4	0
170	Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Blood Transfusion, 2019, 17, 334-335.	0.4	0
171	Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study. Blood, 2021, 138, 4915-4915.	1.4	0
172	Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activity. Thrombosis and Haemostasis, 2002, 88, 750-5.	3.4	0
173	The Von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis. , 2022, 1, .		0